Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.

Date publication

janvier 2019

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PEIGNAUX Karine

Tous les auteurs :
Clément-Zhao A, Tanguy ML, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Savignoni A, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31469859

Résumé

Few data are available concerning the safety of bevacizumab (B) in combination with locoregional radiation therapy (RT). The objective of this study was to evaluate the 5-year late toxicity of concurrent B and RT in non-metastatic breast cancer.

Référence

PLoS ONE. 2019 ;14(8):e0221816